Expression of p16 protein in infantile hemangioma

Wang,Shi; Zheng,Wei

doi:10.3892/ol.2015.3418

Expression of p16 protein in infantile hemangioma

Authors:
- Shi Wang
- Wei Zheng
View Affiliations

Affiliations: Department of Stomatology, The Third Central Hospital, Tianjin 300170, P.R. China, Department of Orthodontics, Tianjin Stomatological Hospital, Nankai University, Tianjin 300041, P.R. China
Published online on: June 24, 2015 https://doi.org/10.3892/ol.2015.3418
Pages: 1589-1592

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression and significance of p16 in the occurrence, development and regression of infantile hemangioma (IH). The expression of p16 was examined in proliferating, involuting hemangioma and normal tissues using immunohistochemical techniques. The expression of p16 was significantly lower in proliferating hemangioma than in involuting hemangioma, and was significantly lower in the involuting hemangioma than in normal tissues. Significant differences were found between the three groups (P<0.05). The results indicate that p16 may be important in the regression of IH endothelial cells and in anti‑angiogenesis. There is a certain association between p16 expression and the regression of hemangioma. This provides a theoretical basis for the further study of the pathological mechanisms of p16 in hemangioma and potential gene therapies that may treat this disease.

View Figures

View References

1	Sans V, Dumas de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, Lipsker D, Dupuis E, Ezzedine K, Vergnes P, et al: Propanolol for severe infantile hemangiomas: Follow-up report. Pediatrics. 124:e423–e431. 2009. View Article : Google Scholar : PubMed/NCBI
2	Chen TS, Eichenfield LF and Friedlander SF: Infantile hemangiomas: An update on pathogenesis and therapy. Pediatrics. 131:99–108. 2013. View Article : Google Scholar : PubMed/NCBI
3	Yang B, House MG, Guo M, Herman JG and Clark DP: Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol. 18:412–420. 2005. View Article : Google Scholar : PubMed/NCBI
4	Ekholm SV and Reed SI: Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 12:676–684. 2000. View Article : Google Scholar : PubMed/NCBI
5	Li J, Poi MJ and Tsai MD: Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry. 50:5566–5582. 2011. View Article : Google Scholar : PubMed/NCBI
6	Bachmann IM, Straume O and Akslen LA: Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol. 25:1559–1565. 2004.PubMed/NCBI
7	Witkiewicz AK, Knudsen KE, Dicker AP and Knudsen ES: The meaning of p16(ink4a) expression in tumors: Functional significance, clinical associations and future developments. Cell Cycle. 10:2497–2503. 2011. View Article : Google Scholar : PubMed/NCBI
8	Mulliken JB and Glowacki J: Hemangiomas and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr Surg. 69:412–422. 1982. View Article : Google Scholar : PubMed/NCBI
9	Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
10	Li W, Sanki A, Karim RZ, Thompson JF, Soon Lee C, Zhuang L, McCarthy SW and Scolyer RA: The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology. 38:287–301. 2006. View Article : Google Scholar : PubMed/NCBI
11	Khoo CM, Carrasco DR, Bosenberg MW, Paik JH and Depinho RA: Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc Natl Acad Sci U S A. 104:3931–3936. 2007. View Article : Google Scholar : PubMed/NCBI
12	Horbinski C, Nikiforova MN, Hagenkord JM, Hamilton RL and Pollack IF: Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol. 14:777–789. 2012. View Article : Google Scholar : PubMed/NCBI
13	de Andrade BA, León JE, Carlos R, Delgado-Azañero W, Mosqueda-Taylor A and de Almeida OP: Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma. Head Neck Pathol. 6:297–304. 2012. View Article : Google Scholar : PubMed/NCBI
14	Goto T, Mizukami H, Shirahata A, Yokomizo K, Kitamura YH, Sakuraba K, Saito M, Ishibashi K, Kigawa G, Nemoto H, et al: Methylation of the p16 gene is frequently detected in lymphatic-invasive gastric cancer. Anticancer Res. 30:2701–2703. 2010.PubMed/NCBI
15	Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:436–440. 1994. View Article : Google Scholar : PubMed/NCBI
16	Lo K, Mihm M and Fay A: Current theories on the pathogenesis of infantile hemangioma. Semin Ophthalmol. 24:172–177. 2009. View Article : Google Scholar : PubMed/NCBI
17	Phung TL, Hochman M and Mihm MC: Current knowledge of the pathogenesis of infantile hemangiomas. Arch Facial Plast Surg. 7:319–321. 2005. View Article : Google Scholar : PubMed/NCBI
18	Volgareva G, Zavalishina L, Andreeva Y, Frank G, Krutikova E, Golovina D, Bliev A, Spitkovsky D, Ermilova V and Kisseljov F: Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer. 4:582004. View Article : Google Scholar : PubMed/NCBI